CN102895665A - Preparation method of targeting graphene nano-grade drug carrier - Google Patents
Preparation method of targeting graphene nano-grade drug carrier Download PDFInfo
- Publication number
- CN102895665A CN102895665A CN2012102906331A CN201210290633A CN102895665A CN 102895665 A CN102895665 A CN 102895665A CN 2012102906331 A CN2012102906331 A CN 2012102906331A CN 201210290633 A CN201210290633 A CN 201210290633A CN 102895665 A CN102895665 A CN 102895665A
- Authority
- CN
- China
- Prior art keywords
- graphene nano
- targeting
- preparation
- grade
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a preparation method of a targeting graphene nano-grade drug carrier. The method comprises the steps that: a graphene nano-grade material, a hydrophobic anticancer drug, tumor-targeting molecules, and dopamine are mixed in a water solution; the obtained mixture is subjected to ultrasonic uniform dispersion; a pH value of the mixture is regulated such that the mixture is alkaline; the mixture is stabilized for a certain period of time under magnetic stirring and protection from light; the mixture is subjected to centrifugal separation; and a product is uniformly dispersed in a water solution, such that the targeting graphene nano-grade drug carrier based on the graphene nano-grade material is obtained. The method provided by the invention is characterized in that: dopamine auto-polymerization is induced by the pH value; and the graphene nano-grade material, hydrophobic anticancer drug molecules, and the tumor-targeting molecules are compounded simultaneously during the polymerization process, such that rapid preparation of the targeting drug molecules is realized. The method provided by the invention has the advantages that: the targeting nano-grade drug carrier containing hydrophobic anticancer drug molecules can be rapidly prepared under a water solution environment with a normal temperature; the process of the method is simple, and the operation is convenient; and the method has high practicality and good application prospect.
Description
Technical field
The present invention relates to the Novel Carbon Nanomaterials field, be specifically related to a kind of preparation method of targeting graphene nano pharmaceutical carrier.
Background technology
Malignant tumor is a kind of major disease of serious threat human health.The at present clinical comprehensive means such as traditional early diagnosis, radiotherapy, chemotherapy that still adopt are treated.Yet, because it to sick cell and Normocellular low distinguishing, causes the very big damage to human normal tissue.Therefore, develop the drug-supplying system with tumor cell specific target tropism and in oncotherapy, seem particularly important.Kinds of tumor cells special surface label has been found at present research.The drug-supplying system that is found to be the design cancer target of these tumor cell special surface labels provides effective foundation.With respect to traditional radiation and chemotherapy, targeting drug delivery system is to the high-resolution selectivity of tumor cell, and is very little to Normocellular infringement in therapeutic process, thereby its better efficacy.Therefore, the targeted therapy of tumor is the most desirable approach of oncotherapy.
Used chemotherapeutics mainly contains amycin, 5-fluorouracil, paclitaxel etc. at present.These medicines all are hydrophobic drug, usually need to carry out chemical modification or modification to increase its water solublity to it, improve its drug utilization degree.And conventional method also needs when utilizing these medicines to prepare targeting drug delivery system by at the designed tumor targeted moleculars such as medicament carrier system outside chemical grafting folic acid, this process very complicated, and in the chemical graft process, need to use a large amount of organic solvents, cause the raising of manufacturing cost, also environment is brought bad impact.Along with the proposition of " Green Chemistry " concept, how the method by easy environmental protection prepares targeting tumour medicine drug-supplying system, more and more receives people's concern.
Dopamine is a kind of neurotransmitter that exists in the blood of human body.Research finds that dopamine auto polymerization can occur forms poly-dopamine under certain condition, and poly-dopamine has great similarity with naturally occurring mussel Fibronectin on the Nomenclature Composition and Structure of Complexes.Poly-dopamine can be at nearly all material surface Adhesion formation bonding interface, simultaneously because the activation hydrogen effect on its phenyl ring makes the chemical compound of the reactive groups such as band amino, sulfydryl be easy to be chemically bonded on the poly-dopamine surface.
Graphene is a kind of Two-dimensional Carbon nano material of in recent years finding.Because its unique structure makes it have important application prospect in fields such as biomedicine, composite, sensor, the energy.Because Graphene has the monoatomic layer structure, its theoretical specific surface area is up to 2600 m
2/ g is fit to do pharmaceutical carrier very much.Two basal plane can adsorb medicine simultaneously, so have the unrivaled superelevation carrying drug ratio of other nano materials.And because its large pi-conjugated structure can be passed through π-required hydrophobic drug of π interaction fixation for treatment tumor, this just makes it have a good application prospect aspect drug delivery system.
Summary of the invention
The preparation method that the purpose of this invention is to provide a kind of targeting graphene nano pharmaceutical carrier, this method overcomes the problems referred to above of conventional method, adopting said method can prepare targeting tumour medicine drug-supplying system in easy environmental protection ground, has alleviated to greatest extent environmental pollution.
Principle of the present invention comprises that (1) is that the carrier material that adopts is the graphene nano material, has the characteristics such as specific surface area is large, can pass through π-π interaction association hydrophobic drug, realizes the payload of medicine; (2) be that the formed poly-dopamine layer of biomolecules of dopamine auto polymerization forms shell in graphene nano pharmaceutical carrier outside, have good biocompatibility, provide a kind of adjustable means for the regulating drug rate of release simultaneously; (3) be the characteristic of the spontaneous easy grafting amido polymer in poly-dopamine surface, can convenient environment friendly ground surface grafting folic acid.Utilize dopamine auto polymerization technology, take Graphene as the hydrophobic anticancer drug carrier, in conjunction with the characteristic of the spontaneous easy grafting amido polymer in poly-dopamine surface, the antitumor drug drug delivery system of the surperficial folic acid grafting of the quick environmental protection of energy ground preparation.
Preparation method of the present invention is, adds the hydrophobic anticancer drug molecule, tumor targeted molecular folic acid and dopamine in concentration is the graphene nano material water solution of 0.1 mg/mL-1 mg/mL; With the ultrasonic Uniform Dispersion 10-60 of ultrasonic emulsification machine minute; Regulate pH to 8.0-10.5; The lucifuge magnetic agitation is 2-8 hour on magnetic stirrer, and the stable complex that obtains is collected nano-particle with centrifuge 3000 rpm-11000 rpm centrifugalize 30-60 minute, uses distilled water wash granule at least 3 times; Product is dispersed in the solvent, obtains the targeted nano pharmaceutical carrier based on the graphene nano material, for subsequent use.
In the such scheme, described hydrophobic drug is amycin, or 5-fluorouracil.Amycin, 5-fluorouracil all are hydrophobic anticancer drug, and it is fixing that Graphene can pass through π-π interaction, tests so can choose one among the embodiment wantonly.
In the such scheme, the mass ratio of described graphene nano material and hydrophobic anticancer drug molecule is 1:1-5:1.
In the such scheme, the mass ratio of described graphene nano material and tumor targeted molecular is 2:1 – 4:1.
In the such scheme, the mass ratio of described graphene nano material and dopamine is 1:2-1:8.
In the such scheme, the homodisperse solvent of described product is water, or phosphate physiological buffer solution.
The beneficial effect that the present invention obtains is: this nano medicament carrying system only needs by regulating the pH value in the aqueous solution, induce the generation of dopamine auto polymerization reaction, just can spontaneous grafting folic acid, and do not need chemical graft folic acid just can realize the preparation of target tumor medicament carrier system.And when realizing that environmental protection prepares fast, this nano medicament carrying system can be transported to lesions position with the hydrophobic anticancer drug orientation, thereby improves the drug effect of lesions position, has simultaneously the effect of slow release concurrently.The targeted nano pharmaceutical carrier is high to the envelop rate of medicine, operating process is easy, and reaction condition is gentle, and can compare etc. by the reactant quality and regulate drug loading, that a kind of preparation process is quick and environmental protection, functional and practical novel nano drug-supplying system.
Description of drawings
Fig. 1 is the ultraviolet spectrogram of centrifugal rear supernatant in pure amycin solution and the targeted drug delivery system preparation process.
Fig. 2 is that (DA/GO-(DOX)-FA) is to the cytotoxicity experiment result of people's choroid melanoma cell (OCM-1) for prepared nano-medicament carrier, reference group is simple stannic oxide/graphene nano material (GO), amycin medicine (DOX), and the not nano-carrier of carrying medicament (DA/GO-FA) and the not nano-medicament carrier of grafting targeted molecular (DA/GO (DOX)).
The specific embodiment
Embodiment 1
Be to add 0.8 mg hydrophobic anticancer drug molecule amycin, 1 mg tumor targeted molecular folic acid and 8 mg dopamine in the graphene nano material water solution of 0.1 mg/mL in 40mL concentration; With the ultrasonic Uniform Dispersion of ultrasonic emulsification machine 10 minutes; Regulate pH to 8 with pH meter; Lucifuge stirs 2 hours gained stable complexes; With 3000 rpm rotating speed centrifugalize 60 minutes, collect nano-particle with centrifuge, use distilled water wash granule at least 3 times; Product is dispersed in the water, obtains the targeted nano pharmaceutical carrier based on the graphene nano material, for subsequent use.
Embodiment 2
Be to add 10 mg hydrophobic anticancer drug molecule amycin, 6.7 mg tumor targeted molecular folic acid and 100 mg dopamine in the graphene nano material water solution of 0.5 mg/mL in 40mL concentration; With the ultrasonic Uniform Dispersion of ultrasonic emulsification machine 40 minutes; Regulate pH to 8.5 with pH meter; 5 hours gained stable complexes of lucifuge magnetic agitation on magnetic stirrer; With 7000 rpm rotating speed centrifugalize 40 minutes, collect nano-particle with centrifuge, use distilled water wash granule at least 3 times; Product is dispersed in the phosphate physiological buffer solution, obtains the targeted nano pharmaceutical carrier based on the graphene nano material, for subsequent use.
Embodiment 3
Be to add 40 mg hydrophobic anticancer drug molecule amycin, 20 mg tumor targeted molecular folic acid and 320 mg dopamine in the graphene nano material water solution of 1.0 mg/mL in 40mL concentration; With the ultrasonic Uniform Dispersion of ultrasonic emulsification machine 60 minutes; Regulate pH to 10.5 with pH meter; 8 hours gained stable complexes of lucifuge magnetic agitation on magnetic stirrer; With 11000 rpm rotating speed centrifugalize 30 minutes, collect nano-particle with centrifuge, use distilled water wash granule at least 3 times; Product is dispersed in the phosphate physiological buffer solution, obtains the targeted nano pharmaceutical carrier based on the graphene nano material, for subsequent use.
The targeted nano medicament carrier system of above test preparation can find out that process is environmental protection, and this has greatly reduced the use of organic reagent.The prepared targeting graphene nano pharmaceutical carrier of above-mentioned 3 tests adopts uv analyzer (Uv) to carry out analyzing and testing, the feature uv absorption wavelength of known amycin is 495nm, as can be seen from Figure 1, contain hardly amycin in the supernatant after centrifugal, the targeted nano pharmaceutical carrier that this shows the method preparation reaches 100% to the envelop rate of amycin.As can be seen from Figure 2, prepared nano-medicament carrier is the most obvious to the inhibition of tumor cell OCM-1; Behind the grafting tumor targeted molecular FA, the inhibition of cell is further strengthened.Table 1 is the size of nano-medicament carrier prepared under the various ratio conditions, carrying drug ratio, and the OCM-1 cell is applying the cell survival rate of pharmaceutical carrier after one day.
Table 1
Claims (10)
1. the preparation method of a targeting graphene nano pharmaceutical carrier is characterized in that, adds hydrophobic anticancer drug molecule, tumor targeted molecular and dopamine in graphene nano material water solution; Ultrasonic Uniform Dispersion, regulator solution pH is to alkalescence; Lucifuge stirs the stable complex that obtains, and after centrifugalize product is dispersed in the solvent, obtains the targeted nano pharmaceutical carrier based on the graphene nano material.
2. described preparation method according to claim 1 is characterized in that, the concentration of described graphene nano material water solution is 0.1 mg/mL-1 mg/mL.
3. described preparation method according to claim 1 is characterized in that, described hydrophobic drug is amycin, or 5-fluorouracil.
4. described preparation method according to claim 1 is characterized in that, the mass ratio of described graphene nano material and hydrophobic anticancer drug molecule is 1:1-5:1.
5. described preparation method according to claim 1 is characterized in that, described tumor targeted molecular is folic acid.
6. described preparation method according to claim 1 is characterized in that, the mass ratio of described graphene nano material and tumor targeted molecular is 2:1 – 4:1.
7. described preparation method according to claim 1 is characterized in that, the mass ratio of described graphene nano material and dopamine is 1:2-1:8.
8. described preparation method according to claim 1 is characterized in that, the described Uniform Dispersion time is 10-60 minute.
9. described preparation method according to claim 1 is characterized in that, described pH value of solution is 8.0-10.5.
10. described preparation method according to claim 1 is characterized in that, the described centrifugalize time is 30-60 minute.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210290633.1A CN102895665B (en) | 2012-08-15 | 2012-08-15 | Preparation method of targeting graphene nano-grade drug carrier |
| PCT/CN2012/083873 WO2014026435A1 (en) | 2012-08-15 | 2012-10-31 | Preparation method of targeted graphene nano-drug carrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210290633.1A CN102895665B (en) | 2012-08-15 | 2012-08-15 | Preparation method of targeting graphene nano-grade drug carrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102895665A true CN102895665A (en) | 2013-01-30 |
| CN102895665B CN102895665B (en) | 2014-01-29 |
Family
ID=47568348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210290633.1A Active CN102895665B (en) | 2012-08-15 | 2012-08-15 | Preparation method of targeting graphene nano-grade drug carrier |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102895665B (en) |
| WO (1) | WO2014026435A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784407A (en) * | 2014-02-26 | 2014-05-14 | 哈尔滨医科大学 | Folic acid-mediated (polyethylene glycol) PEG-graphene oxide doxorubicine-loaded nanoparticle and preparation method thereof |
| CN104189917A (en) * | 2014-08-13 | 2014-12-10 | 东华大学 | Preparation method of doxorubicin-containing graphene oxide medicine-carrying composite material |
| CN104399090A (en) * | 2014-11-12 | 2015-03-11 | 深圳先进技术研究院 | Poly dopamine-modified reduced graphene oxide and preparation method and application thereof |
| CN104927302A (en) * | 2014-03-20 | 2015-09-23 | 江南大学 | Graphene-toughened epoxy resin composite material and preparation method thereof |
| CN105153381A (en) * | 2015-09-06 | 2015-12-16 | 江南大学 | Novel method for modifying graphene with polymer |
| CN111467499A (en) * | 2020-04-18 | 2020-07-31 | 中山市君泽科技有限公司 | Graphene-loaded combined cancer treatment method |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618514B (en) * | 2020-04-13 | 2022-04-12 | 华东师范大学 | Ammonia borane/hollow mesoporous polydopamine/polyethylene glycol nano composite particle and preparation and application thereof |
| CN113101370B (en) * | 2021-04-08 | 2022-11-18 | 曲阜师范大学 | Manganese dioxide targeted nano-drug carrier and preparation method and application thereof |
| CN113456672B (en) * | 2021-06-17 | 2023-08-11 | 温州医科大学 | Targeted medicine of chemical kinetics enhancement photothermal therapy system for treating malignant tumor, and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101670108A (en) * | 2009-08-13 | 2010-03-17 | 苏州纳米技术与纳米仿生研究所 | Medicine carrying system based on nano graphene oxide |
| CN102552932A (en) * | 2012-02-09 | 2012-07-11 | 哈尔滨工业大学 | Method for preparing graphene oxide double-targeting medicine carrier material, and loaded medicine |
-
2012
- 2012-08-15 CN CN201210290633.1A patent/CN102895665B/en active Active
- 2012-10-31 WO PCT/CN2012/083873 patent/WO2014026435A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101670108A (en) * | 2009-08-13 | 2010-03-17 | 苏州纳米技术与纳米仿生研究所 | Medicine carrying system based on nano graphene oxide |
| CN102552932A (en) * | 2012-02-09 | 2012-07-11 | 哈尔滨工业大学 | Method for preparing graphene oxide double-targeting medicine carrier material, and loaded medicine |
Non-Patent Citations (4)
| Title |
|---|
| TING-TING ZHENG ET AL.: "A label-free cytosensor for the enhanced electrochemical detection of cancer cells using polydopamine-coated carbon nanotubes", 《ANALYST》 * |
| YING WANG ET AL.: "Graphene and graphene oxide: biofunctionalization and applications in biotechnology", 《TRENDS IN BIOTECHNOLOGY》 * |
| YUJING GUO ET AL.: "Electrochemical Sensor for Ultrasensitive Determination of Doxorubicin and Methotrexate Based on Cyclodextrin-Graphene Hybrid Nanosheets", 《ELECTROANALYSIS》 * |
| 郑龙珍 等: "石墨烯-聚多巴胺纳米复合材料制备过氧化氢生物传感器", 《分析化学》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784407A (en) * | 2014-02-26 | 2014-05-14 | 哈尔滨医科大学 | Folic acid-mediated (polyethylene glycol) PEG-graphene oxide doxorubicine-loaded nanoparticle and preparation method thereof |
| CN103784407B (en) * | 2014-02-26 | 2016-01-20 | 哈尔滨医科大学 | Graphene oxide-loaded adriamycin nano-particles of a kind of folate-mediated PEG-and preparation method thereof |
| CN104927302A (en) * | 2014-03-20 | 2015-09-23 | 江南大学 | Graphene-toughened epoxy resin composite material and preparation method thereof |
| CN104189917A (en) * | 2014-08-13 | 2014-12-10 | 东华大学 | Preparation method of doxorubicin-containing graphene oxide medicine-carrying composite material |
| CN104399090A (en) * | 2014-11-12 | 2015-03-11 | 深圳先进技术研究院 | Poly dopamine-modified reduced graphene oxide and preparation method and application thereof |
| CN105153381A (en) * | 2015-09-06 | 2015-12-16 | 江南大学 | Novel method for modifying graphene with polymer |
| CN111467499A (en) * | 2020-04-18 | 2020-07-31 | 中山市君泽科技有限公司 | Graphene-loaded combined cancer treatment method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102895665B (en) | 2014-01-29 |
| WO2014026435A1 (en) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102895665B (en) | Preparation method of targeting graphene nano-grade drug carrier | |
| CN106139144B (en) | A kind of hyaluronic acid decorated gold-Nano carbon balls and the preparation method and application thereof with synergistic antitumor characteristic | |
| CN104474555B (en) | Meso-porous nano silicon ball complex targeting drug delivery system and its preparation method and application | |
| CN102675655B (en) | Water-soluble fullerene and preparation and application methods thereof | |
| CN104001178B (en) | A kind of PLGA nano-medicament carrier and its preparation method and application | |
| CN110201163A (en) | A kind of load medicine mesoporous TiO 2 nanoparticle of hyaluronic acid and poly-dopamine modification | |
| CN105288620B (en) | A kind of preparation method of Jenner's popped rice for neoplasm targeted therapy | |
| CN101785759B (en) | Nanoparticle for embedding medicinal Adriamycin as well as preparation method and application thereof | |
| CN105030795A (en) | Nanometer drug-loading system as well as preparation method and application thereof | |
| CN105214090B (en) | A kind of Fe3O4The synthetic method of@ZnO core-shell nanospheres | |
| Rafique et al. | Photo-induced reactions for disassembling of coloaded photosensitizer and drug molecules from upconversion-mesoporous silica nanoparticles: an effective synergistic cancer therapy | |
| CN109395087A (en) | A kind of nanometer delivering NO donor and Nano medication altogether is total to delivery system | |
| Zhang et al. | Near infrared light triggered reactive oxygen species responsive nanoparticles for chemo-photodynamic combined therapy | |
| Zhai et al. | Metastable interface biomimetic synthesis of a smart nanosystem for enhanced starvation/gas therapy | |
| Rajasekharreddy et al. | Green synthesized nanomaterials as theranostic platforms for cancer treatment: Principles, challenges and the road ahead | |
| CN104189917A (en) | Preparation method of doxorubicin-containing graphene oxide medicine-carrying composite material | |
| CN105641710B (en) | The targeted oxidative graphene of HA/RGD modification is double to carry medicine composite material and preparation method thereof | |
| Yue et al. | Research progress in the use of cationic carbon dots for the integration of cancer diagnosis with gene treatment | |
| CN103386135B (en) | Preparation method of multifunctional medicine carrier integrating magnetism, fluorescence and thermosensitivity | |
| CN109464676B (en) | Preparation method and product of chitosan oligosaccharide photosensitive targeting nanoparticles | |
| CN112656951B (en) | Cross-linked acid-responsive natural polysaccharide polymer prodrug, preparation method and application | |
| CN109233820A (en) | A kind of g-C3N4Quantum dot and its preparation method and application | |
| CN110251672B (en) | Nano diagnosis and treatment agent and preparation method and application thereof | |
| CN103239410B (en) | Preparation method of fluorescence and heat/pH sensitive organic-inorganic composite microsphere carrier | |
| Zhu et al. | Near-infrared light-activatable melanized paclitaxel nano–self-assemblies for synergistic anti-tumor therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |